Company’s cell manufacturing platform to power regenerative medicine therapies for blindness, hearing loss and bone regeneration.
British biotech Mytos has entered into new partnerships with three biotechnology companies to integrate its automated iDEM cell manufacturing platform into upcoming clinical trials. Touting its system’s potential to support a wide spectrum of regenerative medicine programs, Mytos says that StemSight, Rinri Therapeutics and Novadip will each use the platform to scale production of distinct cell types.
The London-based company has developed a closed, automated system designed to replace traditional induced pluripotent stem cell manufacturing, a process that has long been hindered by cost, variability and scalability challenges. By offering consistent, GMP-compatible production of human cells, Mytos aims to accelerate timelines for life sciences companies while reducing the risks inherent in manual approaches.
StemSight, based in Finland, will use the platform to advance development of its iPSC-derived corneal stem cell therapy for limbal stem cell deficiency, a rare cause of corneal blindness. The company emphasized the need for cost-efficient, scalable processes that can reach patients globally, and sees Mytos’ technology as a bridge from early manual methods to automated production.
In the UK, Rinri Therapeutics is preparing to bring its lead candidate, Rincell-1, into the clinic for the treatment of sensorineural hearing loss. The company will look to Mytos’ automation to ensure precision and reproducibility in manufacturing otic neural progenitor cells, laying the foundation for future expansion and international supply.
Belgium-based Novadip is focused on regenerative bone tissue therapies derived from adipose stem cells and is evaluating how the iDEM system could scale output of its autologous products for patients with large bone defects. The company expects the platform to increase production capacity within its existing facilities, allowing it to move forward without the delays that come with building additional infrastructure.
Mytos says the collaborations highlight how the company’s approach can be adapted to support diverse therapeutic approaches, from ocular and auditory disorders to complex skeletal repair.
“Our mission at Mytos is to scale regenerative medicine to millions of patients, by removing the scalability and cost challenges of manual manufacturing,” said Mytos CEO Dr Ali Afshar. “These three partners represent very different cell types and therapeutic areas, yet each saw the same thing in Mytos, namely our robust, scalable, automated platform that can take them from early clinical trials to commercial-ready manufacturing.”
